The Institute enjoys a strong strategic alliance with the Pediatrics Department at UC San Diego, where many of our researchers and clinicians have faculty appointments. We also engage with the Computer Science and Genomics Departments to bring their fundamental and translational research work into bedside practice at Rady Children’s Hospital-San Diego. Among the other distinguished institutions contributing to our research are the Sanford Burnham Prebys Medical Discovery Institute, The Scripps Research Institute and the University of Washington.
Rady Children’s Institute is a founding member of the Sanford Children’s Genomic Medicine Consortium which involves seven other large children’s hospitals in California, Arizona, Colorado, Miami, Minnesota and the Dakotas. Together with our research partners, we are building the evidence base to demonstrate the clinical and economic value of genomic medicine for the management of rare genetic diseases in pediatric patients.
We are harnessing the power of genomic sequencing and working with children’s hospitals across the country to usher in a new era in Rapid Precision Medicine®. The information we obtain from rapid Whole Genome Sequencing is already informing treatment decisions and improving the lives of children and their families at our partner hospitals.
In addition to Rady Children’s Hospital, our growing list of collaborators includes: CHOC – Children’s Hospital Orange County, Children’s Minnesota, Children’s Colorado, Nicklaus Children’s Hospital (Miami), Helen deVos Children’s Hospital (Michigan), Diamond Children’s Medical Center (Tucson). We are committed to working with these clinical colleagues to expand access to Rapid Precision Medicine® nationwide to children with rare and undiagnosed genetic diseases.
The Institute works closely with leading biotechnology and data-science companies to optimize a seamless end-to-end process that reduces the time and cost of sequencing a genome. Each company has further tailored their technology to meet our stringent clinical diagnostic requirements. Through this collaboration, our scientists have compressed the time needed to decode rare genetic disorders in newborns through genomic sequencing to less than a week, compared to the six or more weeks commonly required by commercial laboratories.
Our ability to deliver life-changing diagnoses for the most critically-ill newborns and children is made possible primarily through grant funding and the generous support of individual, corporate and community donors. By investing in the work of the Institute, our philanthropic partners empower us to advance our mission of making Rapid Precision Medicine® a reality for children’s hospitals nationwide.